Lower tolls and fares on P.E.I.'s Confederation Bridge and ferries starting today
CHARLOTTETOWN — It now costs less for drivers to cross the 12.9-kilometre Confederation Bridge linking Prince Edward Island to Canada's mainland.
Prime Minister Mark Carney announced this week the toll for an average vehicle will drop from $50.25 to $20 to cross the bridge.
About one million vehicles a year drive over the crossing, which opened in 1997, connecting the Island to New Brunswick.
The toll is only applied for vehicles leaving P.E.I.
Other federally supported ferry services in Eastern Canada are also seeing their fares reduced by 50 per cent for passengers, vehicles and commercial traffic.
The federal government estimates the toll and fare reductions will cost about $100 million, but Carney predicted the changes would generate increased traffic and lower the cost of living.
The federal Liberals promised to lower the fares during the April election campaign.
This report by The Canadian Press was first published Aug. 1, 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
8 minutes ago
- Globe and Mail
Aurora Cannabis Pre-Q1 Earnings Analysis: Buy, Sell or Hold the Stock?
Aurora Cannabis ACB is slated to release first-quarter fiscal 2026 results on Aug. 6, before market open. The Zacks Consensus Estimate for earnings and revenues is pegged at 18 cents per share and $70.88 million, respectively. The earnings estimate, which has remained stable over the past seven days, indicates a whopping 263.6% growth year over year. The Zacks Consensus Estimate for quarterly revenues suggests a year-over-year increase of 5.4%. The consensus mark for fiscal 2026 revenues is pegged at $272.1 million, implying a rise of 7.6% year over year, and the same for EPS is pinned at 56 cents, suggesting a year-over-year improvement of 100%. This medical cannabis producer's earnings surpassed the Zacks Consensus Estimate in three of the trailing four quarters and missing once, delivering an average surprise of 50.10%. Q2 Earnings Whispers for Aurora Cannabis Per our proven model, a stock with a Zacks Rank #1 (Strong Buy), 2 (Buy), or 3 (Hold), along with a positive Earnings ESP, has higher chances of beating estimates. This is not the case here, as you can see below. Earnings ESP: ACB has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter. Zacks Rank: The company currently carries a Zacks Rank #4 (Sell). You can see the complete list of today's Zacks #1 Rank stocks here. Factors to Note Ahead of ACB's Q2 Results Aurora Cannabis is slated to report fiscal first-quarter 2026 results later this week, following a record-setting fiscal 2025 driven by its focused 'medical-first' strategy. The upcoming results are expected to reflect sustained momentum in global medical cannabis sales, supported by expanded product offerings, ongoing international market penetration and operational excellence. Australia continues to be a key growth lever, where Aurora Cannabis recently expanded its IndiMed portfolio with the launch of TEMPO 22 cultivars, catering to rising patient demand for high-potency, value-segment medical cannabis. The company's deep-rooted infrastructure and longstanding relationships in the region have fortified its second-highest market share position, with management optimistic about further patient accessibility and product uptake. This is likely to have boosted top-line growth in the soon-to-be-reported quarter. In Europe, strong performance in Germany is likely to have led the top-line growth during the fiscal first quarter, benefiting from cannabis de-scheduling and increasing patient registrations. Aurora Cannabis' strategic focus on ensuring consistent product availability has been crucial, while the ramp-up of German-cultivated IndiMed offerings must have further cemented its leadership. Sales are likely to have been hurt by temporary regulatory headwinds in Poland. However, management remains bullish on the market's long-term growth prospects, underpinned by planned launches of high-quality cultivars. Additionally, the U.K. business is expected to have gained traction from the launch of inhalable cannabis concentrates, an innovative format catering to evolving patient needs. These product introductions mark another step in Aurora Cannabis' mission to diversify dosage forms and enhance patient access in global markets. On the operational front, the recent $3 million upgrade to Aurora Cannabis' Alpine facility in British Columbia has doubled yields and potency, which might have supported top-line growth with a new supply line in place. While management anticipates first-quarter revenues to be slightly lower than the fourth-quarter fiscal 2025 level due to temporary international market fluctuations, margins are expected to remain robust, supported by a favorable product mix and continued cost discipline. Adjusted EBITDA is projected to moderate sequentially but remain positive, maintaining Aurora Cannabis' position as one of the few profitable global cannabis players. ACB Price Performance & Valuation On a year-to-date basis, shares of ACB have gained 5.4%, outperforming its close peers, Tilray Brands TLRY and Canopy Growth CGC and the Medical Products industry. In terms of valuation, Aurora Cannabis trades at a forward 12-month P/S of 0.9 — above Tilray Brands (0.65) and below Canopy Growth (1.07). Despite Tilray Brands offering lower multiples, ACB's premium reflects stronger growth expectations. Moreover, a higher valuation of Canopy Growth despite its declining share price makes it an expensive choice. ACB vs TLRY Image Source: Zacks Investment Research ACB vs CGC Buy Aurora Cannabis Stock Ahead of Q2 Results? While Aurora Cannabis continues to demonstrate strong execution in its global medical cannabis strategy, near-term headwinds warrant a cautious stance. Temporary regulatory disruptions in Poland, competitive pressures in international markets, and the anticipated sequential revenue dip in first-quarter fiscal 2026 temper immediate upside potential. Additionally, while Aurora Cannabis' margin profile remains industry-leading, further scalability in high-margin markets is essential to drive meaningful top-line growth. With the stock's recent gains reflecting much of the operational improvements, it would be wise for investors to await clearer visibility on sustained revenue acceleration and international market stabilization. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Canopy Growth Corporation (CGC): Free Stock Analysis Report Tilray Brands, Inc. (TLRY): Free Stock Analysis Report Aurora Cannabis Inc. (ACB): Free Stock Analysis Report
CTV News
15 minutes ago
- CTV News
Hilary Weston, fashion mogul and former lieutenant-governor of Ontario, dead at 83
Hilary Weston was born in Ireland and spent her early years as a fashion model. She moved to Toronto in the 1970s with her husband, Galen Weston -- a retail magnate who helped turn Loblaw into one of the largest food distributors in the country.
National Post
38 minutes ago
- National Post
Berkshire Hathaway Specialty Insurance Launches Program Business in Canada With David Tran at the Helm
Article content BOSTON & TORONTO — Berkshire Hathaway Specialty Insurance (BHSI) today announced its entry into the Programs market in Canada and named David Tran as Head of Programs, Canada. Article content 'BHSI continues to grow steadily across Canada, expanding our team, our geographic reach, and our product lines,' said Andrew Knight, Country Manager, Canada, BHSI. 'Our move into the Programs space is a natural evolution of our strategy to 'go wide and go deep'—broadening our specialty underwriting capabilities and bringing the security of our strong balance sheet to new segments and distribution partners. I'm thrilled to welcome David, whose extensive expertise will be instrumental in driving this strategic initiative.' Article content Article content David brings more than two decades of experience in underwriting and strategic relationship management to his new role. He was most recently Vice President, National Strategic Relationships at another insurer. In David's new capacity as Head of Programs for BHSI Canada, he will be responsible for launching and leading program strategies which includes a new national platform that delivers insurance solutions through strategic partnerships with program administrators, MGA's and broker partners. David is based in Toronto and can be reached at Article content Berkshire Hathaway Specialty Insurance ( provides commercial property, casualty, healthcare professional liability, executive and professional lines, transactional liability, surety, marine, travel, programs, accident and health, medical stop loss, homeowners, and multinational insurance. The actual and final terms of coverage for all product lines may vary. In Canada it underwrites on the paper of National Liability & Fire Insurance Company, a part of Berkshire Hathaway's National Indemnity group of insurance companies, which hold financial strength ratings of A++ from AM Best and AA+ from Standard & Poor's. Based in Boston, Berkshire Hathaway Specialty Insurance has offices in Atlanta, Boston, Chicago, Columbia, Dallas, Houston, Indianapolis, Irvine, Los Angeles, New York, Plymouth Meeting, San Francisco, San Ramon, Seattle, Stevens Point, Adelaide, Auckland, Barcelona, Brisbane, Brussels, Calgary, Cologne, Dubai, Dublin, Frankfurt, Hamburg, Hong Kong, Kuala Lumpur, London, Lyon, Macau, Madrid, Manchester, Melbourne, Milan, Munich, Paris, Perth, Singapore, Stockholm, Sydney, Toronto, and Zurich. Article content Article content Article content Article content Article content Article content
